Kwangdong Pharmaceutical

At a glance

Kwangdong Pharmaceutical filed 44 disclosures in the last 12 months, including 7 insider, 7 5% holder, 3 buyback and 1 earnings. The most recent key filing was on Oct 12: A major holder's stake rose from 19.42% to 19.42%.

Revenue for 2025 was ₩1.66T, up 1.1% on 2024. Operating margin was 1.9% against 1.8% a year earlier. Debt was 85% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩851B and operating profit of ₩10.3B.

The 2025 annual report lists 1,022 employees with an average tenure of 10.9 years and average pay of ₩78.4M, #485 of 2,191 listed companies by average pay. Its 6 directors and auditors were paid ₩323M each on average. It paid ₩100 per common share in cash dividends, against ₩100 a year earlier (+0%). 최성원 and related parties held 18.19% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 0 cut a stake; the largest stake reported was 19.42% on Oct 12.

From the 2025 annual report

Staff: 1,022 (798 men, 224 women), of whom 21 on fixed-term contracts. Total pay for the year: ₩80.1B. Directors and auditors: 6, paid ₩1.9B in total.

Dividends (common shares)

Largest shareholder

최성원 holds 6.59%; with 15 related parties the group holds 18.19% of common shares at year end (from 17.94% at the start of the year).

Individuals paid ₩500M or more

Auditor: 서현회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports